- Estimated turnaround times based on data on file from previous testing, actual turnaround times may vary.
- If your health care provider did not include your mobile phone number or email address when submitting the lab order, you will not receive an SMS message or email from Exact Sciences.
- Centers for Medicare & Medicaid Services, Medicare Coverage Database. LCD—MolDX: Minimal Residual Disease Testing for Cancer. Accessed January 21, 2025. https://www.cms.gov/
- Diergaarde B, Young G, Hall DW, Mazloom A, Costa G, Subramaniam S, Palomares M, Garces J, Baehner FL, Schoen RE; and other members of the Exact Sciences MRD Group. Circulating tumor DNA as a marker of recurrence risk in Stage III colorectal cancer: The α‐CORRECT study. Journal of Surgical Oncology.
- Dooley et al. Evaluation of whole-exome and whole-genome sequencing tumor-informed circulating tumor DNA MRD assays in patients with early triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy (NAC) with or without olaparib: A prospective sub-study of the PARTNER trial. J Clin Oncol. 44, 570-570(2026).DOI:10.1200/JCO.2026.44.16_suppl.570
- Tsvetanova B, et al. Association for Molecular Pathology 2025 Annual Meeting Abstracts. J Mol Diagn. 2025;27 Suppl:S113.
- Abbott Cancer Diagnostics. Oncodetect v2 Analytical Specificity. Internal presentation. August 25, 2026
The Oncodetect® test was developed, and its performance characteristics determined by Genomic Health, Inc. Performance characteristics may not apply in tumor types not included in this test’s clinical validation. The test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Genomic Health Inc. The Genomic Health Inc. lab performing this test is certified under CLIA regulations and qualified to perform high-complexity clinical laboratory testing.
Oncodetect® is a registered trademark of the Abbott group of companies. All other trademarks are the properties of their respective owners.